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OBJECTIVE—It has been proposed that skeletal muscle insulin
resistance arises from the accumulation of intramyocellular lipid
metabolites that impede insulin signaling, including diacylglyc-
erol and ceramide. We determined the role of de novo ceramide
synthesis in mediating muscle insulin resistance.
RESEARCH DESIGN AND METHODS—Mice were subjected
to 12 weeks of diet-induced obesity (DIO), and then treated for 4
weeks with myriocin, an inhibitor of serine palmitoyl trans-
ferase-1 (SPT1), the rate-limiting enzyme of de novo ceramide
synthesis.
RESULTS—After 12 weeks of DIO, C57BL/6 mice demonstrated
a doubling in gastrocnemius ceramide content, which was com-
pletely reversed (141.5  15.8 vs. 94.6  10.2 nmol/g dry wt) via
treatment with myriocin, whereas hepatic ceramide content was
unaffected by DIO. Interestingly, myriocin treatment did not alter
the DIO-associated increase in gastrocnemius diacyglycerol con-
tent, and the only correlation observed between lipid metabolite
accumulation and glucose intolerance occurred with ceramide
(R  0.61). DIO mice treated with myriocin showed a complete
reversal of glucose intolerance and insulin resistance which was
associated with enhanced insulin-stimulated Akt and glycogen
synthase kinase 3 phosphorylation. Furthermore, myriocin
treatment also decreased intramyocellular ceramide content and
prevented insulin resistance development in db/db mice. Finally,
myriocin-treated DIO mice displayed enhanced oxygen consump-
tion rates (3,041  124 vs. 2,407  124 ml/kg/h) versus their
control counterparts.
CONCLUSIONS—Our results demonstrate that the intramyo-
cellular accumulation of ceramide correlates strongly with the
development of insulin resistance, and suggests that inhibition of
SPT1 is a potentially promising target for the treatment of insulin
resistance. Diabetes 59:2453–2464, 2010
O
besity and type 2 diabetes frequently occur
hand in hand, and are thought of as diseases of
Western society, due to lifestyles characterized
by overnutrition and physical inactivity. This
overnutrition manifests itself as hyperlipidemia, which is
believed to be a major precipitating event in the develop-
ment of skeletal muscle insulin resistance (1,2).
Numerous studies in vivo and in vitro have provided
strong evidence that lipid excess leads to an accumulation
of intramyocellular lipid-derived metabolites, which coin-
cide with an impaired insulin response (3,4). Previous
studies have postulated that this accumulation of lipid-
derived metabolites results from an impaired ability of the
mitochondria to oxidize fatty acids (5–8). Thus, esteriﬁed
fatty acids in the form of long-chain acyl-CoA are diverted
away from carnitine palmitoyl transferase 1, the rate-
limiting enzyme in the mitochondrial uptake and oxidation
of fatty acids, toward triacylglycerol (TAG) and other lipid
metabolites, such as ceramide and diacylglycerol (DAG).
These metabolites are believed to activate classic/novel
protein kinase C isoforms that phosphorylate and inacti-
vate insulin receptor substrate proteins, preventing the
insulin response at the level of Akt and GLUT4 transloca-
tion (3,4).
Of the aforementioned lipid metabolites, ceramide is an
attractive candidate to be a primary culprit involved in
mediating the skeletal muscle insulin resistance seen with
obesity and type 2 diabetes, as it is elevated by both
inﬂammation and nutrient overload, and hence links two
popular models of insulin-resistance development (9).
Numerous studies in both culture and animal models
demonstrate that increasing ceramide levels inhibit insulin
signaling and cause insulin resistance (10–13). Moreover,
Holland et al. showed that inhibiting de novo synthesis of
ceramide by pharmacological inhibition of serine palmi-
toyl transferase one (SPT1) can prevent insulin resistance
caused by corticosteroids, saturated fats, and genetic
models of obesity (12). Pharmacological inhibition of
SPT1 in human muscle cells has also been shown to
prevent the inhibition of insulin-stimulated glycogen syn-
thesis induced by palmitic acid (11). Finally, improve-
ments in insulin sensitivity brought about by exercise
training in obese patients are associated with signiﬁcant
reductions in intramyocellular ceramide levels, whereas
TAG and DAG levels were either unchanged or showed
only a trend to a reduction (14,15).
Our objective in this investigation was to determine if
inhibition of de novo ceramide synthesis could reverse the
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mice, and to gain a further understanding of how cer-
amides affect insulin sensitivity in muscle.
RESEARCH DESIGN AND METHODS
An expanded RESEARCH DESIGN AND METHODS section and supplementary ﬁgures
can be found in an online data supplement available at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1293/DC1. Details on glucose and
insulin tolerance testing, plasma insulin level determination, lipid metabolite
measurement, metabolomics, exercise capacity studies, whole-body in vivo
metabolic assessment, and immunoblot analysis are provided in the online
data supplement.
All animals received care according to the Canadian Council on Animal
Care and the University of Alberta Health Sciences Animal Welfare Commit-
tee. Twelve-week-old C57BL/6 mice were placed on a standard chow/low-fat
diet (4% kcal from lard) or high-fat diet (60% kcal from lard, Research Diets;
D12492) for a 12-week period. At the end of week 12, animals were injected
intraperitoneally every other day with the SPT1 inhibitors, myriocin (0.5
mg/kg) suspended in 1x PBS, L-cycloserine (25 mg/kg) suspended in 1x PBS,
or vehicle control for a 4-week period. At the end of the 4-week treatment
protocol, animals were killed via intraperitoneal injection of sodium pento-
barbital (12 mg) in the fed state in the middle of the dark cycle. Tissues were
excised and immediately frozen in liquid N2. In another study, 6-week-old
db/db mice and their heterozygous controls (db/) (Jackson Laboratories)
were placed on an identical 4-week treatment regimen.
RESULTS
Chronic high-fat feeding results in dramatic weight
gain, whole-body insulin resistance, and altered sub-
strate preference. As expected, mice fed a high-fat diet
for 12 weeks became obese as indicated by a signiﬁcant
increase in weight gain, (supplementary Fig. 1A), and
became insulin resistant (supplementary Fig. 1B–D). Diet-
induced insulin-resistant and lean mice were placed in a
comprehensive lab animal-monitoring system (CLAMS)
for whole-body metabolic assessment, which demon-
strated a high-fat diet–induced shift in fuel preference
toward fatty acids as an oxidative energy source, indicated
by the large drop in the respiratory exchange ratio (RER)
(supplementary Fig. 2A and B). Further support for an
increase in fatty acid oxidation in obese mice is seen with
the increase in gastrocnemius -hydroxyacyl-CoA dehy-
drogenase (HAD) activity (Table 1). Contrary to previous
ﬁndings (16,17), we also report here that obesity induced
by chronic high-fat feeding impairs whole-body oxygen
consumption rates (supplementary Fig. 2C and D).
Inhibition of de novo ceramide synthesis via pharma-
cological inhibition of SPT1 reverses diet-induced
insulin resistance. After 12 weeks of low- or high-fat
diet, mice were treated with either myriocin (0.5 mg/kg
every other day) or vehicle control. After 2 weeks of
treatment, we demonstrated that inhibition of SPT1 with
myriocin reverses diet-induced insulin resistance, as de-
termined by glucose tolerance and insulin tolerance test-
ing (Fig. 1A–D). To determine if these protective effects
took place at the skeletal muscle level, a group of animals
were killed at 30 min after insulin injection during the
insulin tolerance test, and muscles were excised and
harvested for immunoblot analysis of the insulin-signaling
pathway. We demonstrate that insulin stimulation of both
Akt and glycogen synthase kinase 3 (GSK3) phosphor-
ylation were signiﬁcantly improved in the gastrocnemius
muscle of obese mice treated with myriocin (Fig. 1E and
F). Phosphorylation of 5AMP activated protein kinase
(AMPK), another key signaling molecule regulating glu-
cose metabolism, did not differ in gastrocnemius muscle of
control and myriocin-treated obese mice (data not
shown).
Myriocin treatment was without effect on food intake,
body weight, and plasma insulin levels, but did reduce
both postprandial and fasted plasma glucose levels in
obese, insulin-resistant mice (Table 2). Although fasting
plasma insulin levels did not differ between diet-induced
obesity (DIO) mice treated with vehicle-control or myri-
ocin, more sophisticated studies monitoring the changes
in plasma insulin in response to a meal tolerance test in
the obese JCR:LA cp rat illustrate a signiﬁcant improve-
ment in plasma insulin control after treatment with the
SPT1 inhibitor, L-cycloserine (supplementary Fig. 3). Inter-
estingly, indirect calorimetry revealed that the improved
insulin sensitivity in DIO mice treated with myriocin was
not associated with a decrease in fatty acid oxidation and
an increase in carbohydrate oxidation, as similar RER
values were observed between the DIO control and myri-
ocin-treated animals (Fig. 2).
In a parallel series of experiments, after 12 weeks of
high-fat feeding, mice were treated with either the SPT1
inhibitor, L-cycloserine (25 mg/kg every other day) or
vehicle control. Although not as dramatic as the results
observed with myriocin, at 2 weeks after treatment, we
report improvements in glucose and insulin tolerance in
mice treated with L-cycloserine (supplementary Fig. 4).
Inhibition of de novo ceramide synthesis via pharma-
cological inhibition of SPT1 reverses diet-induced
impairments in exercise capacity, which coincide
with a restoration of whole-body oxygen consump-
tion rates and inhibition of fatty acid oxidation.
Obese, insulin-resistant mice were run on an exercise
treadmill to determine exercise capacity. As expected,
obese mice showed a dramatic reduction in both their
treadmill time and distance when compared with their
lean counterparts (Fig. 3A and B). Interestingly, treatment
of obese mice for 2 weeks with myriocin reversed this
reduction in exercise capacity (Fig. 3A and B). This
improvement in exercise capacity observed in obese mice
treated with myriocin can be explained by enhanced
whole-body oxygen consumption rates compared with
their control counterparts (Fig. 4A–C). In addition, we
observed greater citrate synthase activity in gastrocne-
mius muscle of obese mice treated with myriocin (Fig.
4D). Furthermore, protein expression of peroxisome pro-
liferator-activated receptor- coactivator-1 (PGC1), a
transcriptional coactivator that plays a key role in regulat-
ing a number of genes involved in energy metabolism (18),
showed a trend toward a reduction in control-treated DIO
TABLE 1
-hydroxyacyl-CoA dehydrogenase (HAD) activity in gastrocnemius muscle of lean and obese mice treated with vehicle control or
myriocin
LF Control LF myriocin HF control HF myriocin
HAD activity 3.05  0.29 3.19  0.52 4.28  0.31* 4.98  0.60*
Values reported are mol/g wet weight/min of n  5 mice. Differences were determined using a two-way ANOVA followed by Bonferroni post
hoc analysis. *Signiﬁcantly different from the low-fat counterpart. LF, low-fat diet; HF, high-fat diet.
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DIO mice (Fig. 4E). Furthermore, we also demonstrate
that pretreatment with myriocin increases citrate synthase
activity in C2C12 myotubes exposed to 1.0 mmol/l palmi-
tate for 16 h (Fig. 4F). These observations illustrate
improvements in mitochondrial function, possibly explain-
ing why exercise capacity and whole-body oxygen con-
sumption rates were enhanced in this group.
Metabolic proﬁling of mice provided further insight with
regards to mitochondrial function in obese, insulin-resis-
tant mice, as control-treated DIO mice had a signiﬁcant
increase in long-chain acyl carnitine esters versus their
lean counterparts (Table 3), indicative of mitochondrial
overload and the incomplete oxidation of fatty acids (19).
However, the accumulation of long-chain acyl carnitine
esters in myriocin-treated DIO mice was even greater
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FIG. 1. Inhibition of serine palmitoyl transferase 1 (SPT1) reverses high-fat diet–induced insulin resistance and improves insulin signaling. A:
Glucose tolerance test in low-fat–fed and obese insulin-resistant mice treated with either vehicle control or myriocin. B: Area under the curve
during the glucose tolerance test. C: Insulin tolerance test in low-fat diet and obese insulin-resistant mice treated with either vehicle control or
myriocin. D: Percent change in blood glucose levels during the insulin tolerance test. E: Insulin-stimulated Akt phosphorylation at serine 473, and
(F) GSK3 phosphorylation at serine 9 in gastrocnemius muscle of obese insulin-resistant mice treated with either vehicle control or myriocin.
Values represent mean  SE (n  8–12 for A–D; n  4 for E and F). Differences were determined using either a two-tailed Student t test or a
two-way ANOVA followed by a Bonferroni post hoc analysis. *P < 0.05, signiﬁcantly different from all other groups. †P < 0.05, signiﬁcantly
different from the high-fat diet control mice.
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tion rates were even more pronounced in the myriocin-
treated DIO mice, but these animals also had a signiﬁcant
reduction in short-chain acyl carnitine ester content (Ta-
ble 3), which is consistent with long-chain acyl-CoA dehy-
drogenase inhibition and reduced oxidation of long-chain
fatty acids.
Inhibition of de novo ceramide synthesis via pharma-
cological inhibition of SPT1 reverses diet-induced
impairments on heat production with no effect on
animal activity. After 3 weeks of treatment with myri-
ocin, in vivo heat production and ambulatory activity were
assessed in our CLAMS apparatus. Paralleling our obser-
vations with regard to whole-body oxygen consumption
rates, obesity caused a decline in whole-body heat produc-
tion that was reversed by myriocin treatment (supplemen-
tary Fig. 5A and B). Moreover, obesity-induced insulin
resistance was associated with reductions in physical
activity that were not altered by myriocin treatment (sup-
plementary Fig. 5C–E).
Inhibition of de novo ceramide synthesis via pharma-
cological inhibition of SPT1 has no effect on the
obesity-associated increase of long-chain acyl-CoA
and DAG accumulation in muscle, but signiﬁcantly
elevates TAG levels. Investigation of the lipid metabolite
proﬁle in gastrocnemius muscle demonstrated that
chronic high-fat feeding increased long-chain acyl-CoA,
ceramide and DAG content, but only a trend to an increase
in TAG content was observed (Fig. 5A–D). Treatment with
myriocin in obese mice increased gastrocnemius TAG
content in comparison to their low-fat counterparts, but
did not change the DIO-associated rise in long-chain
acyl-CoA and DAG content, and as expected, resulted in a
dramatic reduction in ceramide content (Fig. 5A–D).
These results suggest a key role for ceramide in mediating
skeletal muscle insulin resistance, and indicate that the
other lipid metabolites possibly may not be as important in
the insulin-resistance development. Further support for
this statement is seen with the positive correlation be-
tween ceramide content and the area under the curve
during the glucose tolerance test, whereas no correlation
was observed with any of the other lipid metabolites (Fig.
5E–H). Interestingly, in a previous study, we showed that
mice deﬁcient for malonyl CoA decarboxylase (MCD	/	)
are protected from obesity-induced glucose intolerance
and insulin resistance, which was associated with a reduc-
tion in incomplete fatty acid oxidation rates (19). In this
study we show that these same MCD	/	 mice do not
accumulate ceramide in their gastrocnemius muscle after
12 weeks of high-fat feeding (Fig. 6), although they did
accumulate other lipid metabolites such as long-chain
acyl-CoA (19).
Inhibition of de novo ceramide synthesis via pharma-
cological inhibition of SPT1 prevents the develop-
ment of insulin resistance in leptin receptor deﬁcient
type 2 diabetes db/db mice. To determine if ceramides
may also be involved in genetic forms of insulin resistance
and type 2 diabetes, we treated leptin receptor deﬁcient
(db/db) mice with myriocin to see if we could prevent the
progression of insulin resistance in these animals. We split
TABLE 2
Effect of myriocin on body and tissue weight, and plasma glucose and insulin levels in lean and obese mice
LF control LF myriocin HF control HF myriocin
Body weight (g) 29.80  0.20 28.26  0.77 43.73  0.98* 41.77  0.94*
Fed blood glucose (mM) 8.35  0.39 7.74  0.41 12.39  1.86* 8.65  0.55
Fasted blood glucose (mM) 6.24  0.26 6.29  0.22 7.44  0.49* 6.26  0.22†
Fasted plasma insulin (ng/ml) 0.32  0.02 0.42  0.02 3.95  0.30* 4.73  0.83*
Liver weight (g) 1.41  0.04 1.23  0.04 1.63  0.10 1.32  0.06†
Abdominal fat weight (g) 0.43  0.06 0.71  0.28 1.53  0.17* 1.51  0.10*
Values reported are from n  5–11 mice. Differences were determined using a two-way ANOVA followed by Bonferroni post hoc analysis.
*Signiﬁcantly different from the low-fat counterpart; †Signiﬁcantly different from high-fat control. LF, low-fat diet; HF, high-fat diet.
R
E
R
 
0:00 6:00 12:00  18:00 24:00 
Time (24 hr) 
Dark Cycle  Light Cycle 
0.93 
0.82 
0.71 
0.60 
A  Low-Fat Control 
Low-Fat Myriocin 
High-Fat Control 
High-Fat Myriocin 
B  Control 
Myriocin 
0.9 
0.6 
0.3 
0 
R
E
R
 
Low-Fat Diet  High-Fat Diet 
Dark Cycle 
C  Control 
Myriocin 
0.9 
0.6 
0.3 
0 
R
E
R
 
Low-Fat Diet  High-Fat Diet 
*  * 
Light Cycle 
*  * 
FIG. 2. Substrate preference in lean and obese mice. Twenty-four-hour (A), dark cycle (B), and light cycle respiratory exchange ratio (C)i n
low-fat–fed and obese insulin-resistant mice treated with either vehicle control or myriocin. Values represent mean  SE (n  8–12). Differences
were determined using a two-way ANOVA followed by a Bonferroni post hoc analysis. *P < 0.05, signiﬁcantly different from the low-fat diet
counterpart.
CERAMIDES AND SKELETAL MUSCLE INSULIN RESISTANCE
2456 DIABETES, VOL. 59, OCTOBER 2010 diabetes.diabetesjournals.orgdb/db mice at 6 weeks of age into two groups, and ensured
that there were no differences in glucose tolerance before
initiating treatment with myriocin (Fig. 6A). Both the db/db
control and myriocin-treated groups experienced similar
body weight increases after 2 weeks of treatment (data not
shown), however, although the db/db control group be-
came glucose intolerant, the db/db group treated with
myriocin did not (Fig. 7B and C). Fasting blood glucose
levels were also signiﬁcantly lower in the db/db mice
treated with myriocin, and although their response to
insulin was delayed, myriocin-treated db/db mice demon-
strated lower blood glucose levels at nearly all time points
during an insulin tolerance test (Fig. 7D–F). Placing these
animals in the CLAMS apparatus yielded a proﬁle similar
to that of the DIO mice. The db/db controls had a lower
RER in the dark cycle than db/ lean mice, and had lower
whole-body oxygen consumption rates and ambulatory
activity, but no change in overall heat production; inter-
estingly, myriocin treatment of db/db mice did not restore
any of these altered parameters in db/db controls, except
for a restoration of whole-body oxygen consumption rates
during the light cycle (Fig. 8A–D). Examination of the lipid
metabolite proﬁle revealed that TAG and long-chain acyl-
CoA levels were elevated in gastrocnemius muscle of
db/db controls versus db/ lean mice, whereas, unexpect-
edly, DAG and ceramide levels were similar between the
two groups (Fig. 8E–H). Myriocin treatment of db/db mice
had no effect on TAG, long-chain acyl-CoA, or DAG levels
in gastrocnemius muscle versus db/db control mice, but
did lead to a dramatic reduction in ceramide levels (Fig.
8E–H). Insulin-stimulated Akt and GSK3 phosphorylation
were also depressed in db/db control versus db/ lean
mice, but showed an improvement in db/db mice treated
with myriocin (Fig. 8I and J).
DISCUSSION
Our results show that inhibition of SPT1 reduces de novo
ceramide synthesis in muscle, which has novel effects on
whole-body energy metabolism and is associated with a
profound reversal of glucose intolerance and insulin resis-
tance induced by chronic high-fat feeding. Furthermore,
we show that these improvements are dissociated from
the other lipid metabolites believed to play a role in the
development of insulin resistance. Interestingly, obesity-
induced insulin resistance in mice is associated with a
detriment in aerobic exercise capacity and whole-body
oxygen consumption rates, both of which are partially
reversed via SPT1 inhibition.
Previous studies have postulated that skeletal muscle
insulin resistance is caused by the intramyocellular cyto-
solic accumulation of lipid metabolites (TAG, long-chain
acyl-CoA, DAG, ceramide, etc.) that negatively impact the
insulin signaling cascade (2–4,8,20,21). In particular, long-
chain acyl-CoA and DAG have received considerable at-
tention because of their ability to activate the classic/novel
protein kinase C signaling cascade, which can phosphor-
ylate insulin receptor substrate proteins on serine resi-
dues, preventing their activation via the insulin receptor
(4,5,8,21–23). It is important to note, however, that most
(
95%) acyl-CoA esters are located inside the mitochon-
dria (24,25), suggesting that if long-chain acyl-CoA accu-
mulation does play a role toward insulin resistance
development, it is possible that mitochondrial, as opposed
to cytosolic long-chain acyl-CoA, is the primary contribu-
tor. Although TAG has been shown in numerous studies to
be elevated in muscle in association with the development
of insulin resistance, recent studies have shown that TAG
may actually serve as a buffer, protecting the muscle
against the accumulation of the more reactive lipid metab-
olite species (10,11).
In regards to ceramide, data are mixed with its role in
insulin resistance development, because in some studies,
ceramide accumulation is not evident in muscle (5,26), and
in other studies where accumulation does occur, the
relative increase in the ceramide pool is not that large
(12,27). However, a recent study by Holland et al. (12) has
shed some light on this issue, as they demonstrated that
ceramide accumulation in muscle is dependent on the type
of diet fed to the animals. In particular, saturated fatty
acids drive de novo ceramide synthesis in muscle via
SPT1, whereas unsaturated fatty acids cause insulin resis-
tance via other mechanisms (12). Such ﬁndings may
potentially explain why ceramide accumulation is not
observed in studies of insulin resistance where the model
employed is a lipid infusion that consists primarily of
unsaturated fatty acids (22). Furthermore, Holland et al.
(12) showed in their study that preventing de novo syn-
thesis of ceramide via SPT1 inhibition with myriocin
prevented the development of glucose intolerance in
obese Zucker rats, and prevented the palmitate-induced
inhibition of insulin-stimulated 2-deoxyglucose uptake in
isolated soleus muscle.
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positive ﬁndings with myriocin treatment in leptin-deﬁ-
cient and DIO mice, providing further support that cer-
amide plays a key role in the development of insulin
resistance. Interestingly, these authors also observed a
weight loss effect due to myriocin treatment that we did
not observe in our studies. However, the authors in this
study used a much longer treatment than ours (8 vs. 4
weeks), and noted that they did not observe a weight loss
effect until later in the treatment period. Furthermore, 3
weeks of myriocin treatment in DIO mice improved hyper-
glycemia and whole-body oxygen consumption rates in
their mice, despite no change in body weight compared
with control-treated DIO mice, which is consistent with
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Yang et al. also observed a dramatic reduction in hepatic
steatosis that is consistent with our observations in re-
gards to hepatic TAG content.
Our study adds further support to the studies examining
the role of ceramide in mediating insulin resistance (12,28)
by illustrating the potential for targeting SPT1 as a treat-
ment against insulin resistance. Our data highlight that
targeting SPT1 can be used to reverse insulin resistance in
DIO. Moreover, by examining other lipid metabolites such
as TAG, DAG, long-chain acyl-CoA, and acyl carnitine
content in skeletal muscle, we are able to discern impor-
tant differences with regard to the relative importance of
each metabolite toward the development of skeletal mucle
insulin resistance.
Importantly, reductions in skeletal muscle ceramide
accumulation may represent a potential explanation for
the “exercise paradox” observed in humans. Dube et al.
(15) showed that obese, insulin-resistant men placed on an
aerobic exercise training regime have elevated intramyo-
cellular lipid and TAG stores. However, marked reductions
in muscle ceramide levels are observed, which may ex-
plain the enhanced insulin sensitivity of these men. More-
over, Bruce et al. (14) showed that the improved insulin
sensitivity observed with exercise training in humans is
associated with a drop in muscle ceramide levels, and in
particular, the saturated species. Animal studies of exer-
cise have also yielded similar ﬁndings, as Dobrzyn et al.
(29) showed that exercise training of rats leads to a
dramatic drop in the saturated species of ceramide in
muscle, which is associated with an enhanced 2-deoxyglu-
cose uptake. In addition, mice overexpressing diacylglyc-
erol acyl transferase in muscle are protected from high-
fat-diet–induced insulin resistance and palmitate
inhibition of 2-deoxyglucose uptake in isolated muscle,
both of which are associated with an elevation of muscle
TAG and drop in ceramide levels (10). Our results support
these studies, as we show that obese, insulin-resistant
mice treated with myriocin had signiﬁcant increases in
intramyocellular TAG, long-chain acyl-CoA, and DAG, but
a dramatic drop in ceramide content. Moreover, we ob-
served a positive correlation with ceramide content and
glucose intolerance, but not with any of the other lipid
metabolites. We believe that with this ﬁnding, in the
setting of obesity, that ceramide may be more vital to the
development of skeletal muscle insulin resistance than
the other lipid metabolites. Support for this statement is
also evident in culture models of ceramide accumulation,
whereby inhibition of SPT1 was able to prevent palmitate-
induced insulin resistance in both human and rat L6
myotubes, despite elevated TAG and DAG levels (11,13).
Furthermore, a recent study in humans demonstrated that
insulin resistant muscle is associated with elevated cer-
amide content, but no change in DAG content (30). None-
theless, it is also important to note that our measurement
of DAG assessed total cellular levels of DAG, and it is
possible that differences in plasma membrane DAG were
signiﬁcantly reduced via myriocin treatment. Because
DAG at the membrane is believed to be the speciﬁc DAG
pool responsible for mediating skeletal muscle insulin
resistance (3), it will be important for future studies to
investigate this in more detail.
One of the most surprising ﬁndings of this study was
that chronic high-fat feeding resulted in a dramatic decline
in whole-body oxygen consumption rates. The majority of
studies that have examined the effect of high-fat feeding on
whole-body oxygen consumption rates via use of the
CLAMS apparatus have reported elevations in oxygen
consumption rates (16,17). Although the differences be-
tween these studies and ours could be due to the duration
or composition of the diet, we propose two possible
explanations for this observation of ours. First, it has been
reported that obesity-induced insulin resistance causes
mitochondrial dysfunction that results from an impair-
ment of fatty acid oxidative capacity (5–8). Although it
may be possible that our model of insulin resistance is
inducing mitochondrial dysfunction, it is highly unlikely
due to impairments in muscle fatty acid oxidative capac-
ity, as the RER values in obese mice reported in this study
are very close to 0.7, indicating that these animals have no
trouble utilizing fat as an energy source. Nonetheless,
other factors, such as mitochondrial content, protein
expression of electron transport chain (ETC) complexes,
or activity of these complexes, may account for potential
mitochondrial dysfunction and the subsequent impairment
of oxygen consumption rates observed in obese mice
(31,32). However, we did not observe differences in pro-
tein expression of cytochrome C of the ETC in any group
(data not shown). Second, and just as relevant to the
ﬁndings of this study, is that obesity-induced insulin
resistance has been associated with elevated rates of
incomplete fatty acid oxidation, which can arise when
rates of fatty acid oxidation are disconnected from TCA
cycle activity (19,33,34). This disconnect arises due to the
sedentary nature of obese individuals and animals, thus
there is no demand for the TCA cycle to upregulate its
activity to deal with the increased fatty acid supply that is
being utilized as an energy source (19,33,34). If the TCA
cycle is unable to accommodate the increasing acetyl CoA
coming from fatty acid oxidation, reducing equivalents
such as NADH and FADH2 would not donate their elec-
trons to the complexes of the ETC, accounting for the
reduction in oxygen consumption rates.
Our observation of increased accumulation of long-
chain acyl carnitine esters in the muscle of DIO mice is
thus consistent with elevated rates of incomplete fatty
acid oxidation. In contrast, there was an even greater
accumulation of long-chain acyl carnitine esters in myri-
TABLE 3
Metabolic proﬁling of gastrocnemius muscle from lean and obese mice treated with either vehicle control or myriocin
LF control LF myriocin HF control HF myriocin
Short-chain acylcarnitines 2,488  78 2,481  187 2,215  147 1,704  131*
Medium-chain acylcarnitines 18.2  3.5 15.9  4.6 23.5  2.7 22.0  3.4
Long-chain acylcarnitines 56.9  9.3 67.8  19.7 142.5  8.6* 292.3  62.7*†
Short-chain/long-chain acylcarnitine ratio 47.9  5.4 59.81  16.6 18.6  5.0* 7.7  2.2*†
Values reported are in pmol/mg protein from n  6 mice. Differences were determined using a two-way ANOVA followed by Bonferroni post
hoc analysis. *Signiﬁcantly different from the LF counterpart. †Signiﬁcantly different from high-fat control. LF, low-fat diet; HF, high-fat diet.
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even greater rates of incomplete fatty acid oxidation in
these animals. However, myriocin-treated DIO mice actu-
ally had a signiﬁcant reduction in the content of a number
of short-chain acyl carnitine esters, and this, in combina-
tion with the rise of long-chain acyl carnitine esters, is
suggestive of long-chain acyl-CoA dehydrogenase and sub-
sequent long-chain fatty acid oxidation inhibition (35).
Another piece of indirect support for fatty acid oxidation
inhibition with myriocin treatment in DIO mice is the
observation that TAG accumulated in the muscle of these
animals versus their lean counterparts, but not in control-
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tion in fatty acid oxidation-derived NADH would decrease
NADH/NADPH oxidase activity and subsequent superox-
ide production in myriocin-treated DIO mice, which would
contribute toward their improved mitochondrial function.
This improvement in mitochondrial function, coupled to-
gether with improvements in glucose metabolism and
glucose-derived acetyl CoA production for the TCA cycle,
may contribute to the greater oxygen consumption rates in
these animals. Obesity-induced decrements in PGC1 pro-
tein expression might also explain impairments in mito-
chondrial function (34,36,37), and although not signiﬁcant,
we observed a trend toward a reduction in gastrocnemius
PGC1 protein expression in control-treated DIO mice
(P  0.077) that was not evident in myriocin-treated DIO
mice. Interestingly, citrulline levels were increased in
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parts (supplementary Fig. 6). A previous study in humans
showed that supplementation of citrulline enhances aero-
bic oxidative metabolism (38), supporting our ﬁndings of
increased whole-body oxygen consumption rates and
greater exercise time in myriocin-treated DIO mice. How
myriocin and subsequent SPT1 inhibition would inﬂuence
skeletal muscle citrulline levels is currently unknown, but
is undoubtedly an intriguing avenue for future investiga-
tion. In addition, we have previously shown that MCD	/	
mice (a genetic model of fatty acid oxidation deﬁciency)
are protected from obesity-induced insulin resistance.
Interestingly, we show in this study that these exact same
animals do not accumulate ceramide in their muscle after
12 weeks of high-fat feeding, leading to the very intriguing
possibility that intramyocellular ceramide accumulation is
linked to the mitochondrial dysfunction and enhanced
skeletal muscle fatty acid oxidation rates observed in
insulin resistance.
A limitation with our interpretation of whole-body
oxygen consumption rates is that, unlike human studies,
we were unable to normalize our oxygen consumption
rates to lean body mass. It is entirely possible that
whole-body oxygen consumption rates were simply
lower in DIO mice because of a signiﬁcant increase in
overall adiposity, due to fat mass having a lower meta-
bolic rate than lean body mass. However, the fact that
adiposity and body weight were similar between myri-
ocin- and control-treated DIO mice suggests that this
would not be a contributing factor to the higher oxygen
consumption rates observed in the myriocin-treated DIO
mice. Although we believe that the changes accounting
for the greater oxygen consumption rates in myriocin-
treated DIO mice primarily reﬂect the muscle, we can-
not ignore possible contributions from changes in other
peripheral tissues, such as brown adipose tissue and
uncoupling protein activity.
The beneﬁcial effects mediated by inhibition of SPT1
and prevention of de novo ceramide synthesis could
also arise from liver effects in our animals. Regardless,
we did not observe increases in hepatic ceramide con-
tent after diet-induced obesity, and myriocin treatment
had no effect on insulin-stimulated Akt and GSK3 phos-
phorylation in obese mice versus their respective con-
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ceramide observations, recent studies have also shown
that high-fat feeding does not increase ceramide content
in the liver (39), and increases in hepatic ceramide
content via genetic overexpression of either DGAT1 or
DGAT2 does not result in any type of insulin resistance
or inﬂammation (40). Moreover, we reported no differ-
ence during a pyruvate challenge of fasted, obese,
control- or myriocin-treated mice (supplementary Fig.
8), suggesting that gluconeogenic capacity was not
different between the two groups and that the liver
likely does not play a key role with the improved insulin
sensitivity observed in myriocin-treated mice. Regard-
less, we cannot entirely rule out the possibility that the
liver plays a role with the beneﬁt observed during
myriocin treatment, as the DIO-associated rise in he-
patic TAG content was reversed via myriocin treatment,
and thus it will be important for future studies to
delineate the role of hepatic SPT1 in greater depth.
Finally, chronic low-grade inﬂammation has been
shown in a number of studies to play a role in causing
obesity-induced insulin resistance (41–43). Inﬂammatory
and stress kinases, such as p38 MAPK and JNK, have been
proposed to be downstream mediators of this inﬂamma-
tory effect, as inhibitors of both kinases are able to prevent
high-fat diet–induced insulin resistance (9,44–46). Unex-
pectedly, the phosphorylation status of both p38 MAPK
and JNK was not altered by DIO, nor was it altered by
myriocin treatment (supplementary Fig. 9), suggesting that
inﬂammation may not play as vital a role in our model of
insulin resistance. It may also be possible that inﬂamma-
tion in our model is mediated by some other kinase, such
as IKK (47,48).
With regard to the ﬁndings in db/db mice, we report very
similar ﬁndings to what we observed in the obesity-
induced insulin-resistant mice, and that treatment with
myriocin also yielded a very similar beneﬁcial proﬁle.
Interestingly, gastrocnemius ceramide levels, although re-
duced in myriocin-treated db/db mice, did not differ be-
tween db/ lean and db/db control mice. This suggests, at
least in this model, that perhaps ceramide metabolites,
such as glucosylceramide, are more important in mediat-
ing skeletal muscle insulin resistance than ceramide itself
(49). Furthermore, the ceramide pool is under a dynamic
process of synthesis and degradation (9), and although de
novo synthesis of ceramide may be increased in these
animals, a simultaneous increase in ceramide degradation
would mask out any noticeable change.
In summary, we show that ceramide accumulation in
skeletal muscle plays a key role during obesity-induced
insulin resistance, whereas the other lipid metabolites,
such as TAG, long-chain acyl-CoA, and DAG, may not be as
vital. Importantly, inhibition of de novo ceramide synthesis
has novel effects on whole-body energy metabolism and is
sufﬁcient to reverse obesity-induced whole-body glucose
intolerance and insulin resistance. Furthermore, whole-
body oxygen consumption rates and exercise capacity in
obese mice are improved via inhibition of de novo cer-
amide synthesis. Last, our ﬁnding that muscle ceramide
levels are not elevated in db/db mice, but that inhibition of
de novo ceramide synthesis still prevents their develop-
ment of insulin resistance, suggests the possibility that
ceramide metabolites may also play a role in the progres-
sion of this disease.
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